Early research suggests that low-dose ketamine can produce rapid and significant reductions in PTSD symptoms. A landmark 2014 randomized controlled trial by Feder and colleagues found that a single ketamine infusion at 0.5 mg/kg significantly reduced PTSD symptom severity within 24 hours compared to midazolam placebo. However, the evidence base remains limited, and ketamine is not yet considered a first-line or established treatment for PTSD. Its use for this indication is off-label and typically reserved for patients who have not responded to standard PTSD therapies.
What the Research Shows
The Feder et al. (2014) study, published in JAMA Psychiatry, was the first randomized controlled trial to evaluate IV ketamine specifically for PTSD. The study found rapid improvement in PTSD symptom scores on the Impact of Event Scale, with effects emerging within 24 hours. A follow-up study by the same group (2021) examined repeated ketamine infusions over 2 weeks in chronic PTSD patients, finding significant symptom reduction compared to midazolam, with benefits persisting for weeks after the treatment course.
Additional studies have found that ketamine reduces symptoms across multiple PTSD symptom clusters, including intrusive memories, avoidance, negative mood changes, and hyperarousal. Patients with comorbid depression and PTSD appear to benefit particularly, as ketamine simultaneously addresses both conditions.
Why Ketamine May Help PTSD
PTSD involves dysregulated fear circuits connecting the amygdala, hippocampus, and prefrontal cortex. The amygdala becomes hyperactive, generating exaggerated fear responses, while the prefrontal cortex loses its ability to regulate these responses effectively. Impaired hippocampal function contributes to the intrusive, fragmented nature of traumatic memories.
Ketamine promotes rapid neuroplasticity -- the formation of new synaptic connections -- in these exact brain regions. By stimulating BDNF release and synaptogenesis in the prefrontal cortex and hippocampus, ketamine may help restore the brain's capacity to regulate fear responses and process traumatic memories more adaptively. This neuroplastic window may also enhance the effectiveness of concurrent psychotherapy, which is why some clinicians are exploring ketamine-assisted psychotherapy protocols for trauma treatment.
It is important to note that ketamine's dissociative effects may be distressing for some trauma survivors, and careful clinical assessment is essential before treatment.
For a complete overview of ketamine therapy, see the Complete Guide to Low-Dose Ketamine Therapy.
References
- PubMed: Efficacy of Intravenous Ketamine for Treatment of Chronic PTSD: A Randomized Clinical Trial — Feder et al. (2014), the first RCT of ketamine for PTSD
- NIMH: Post-Traumatic Stress Disorder — National Institute of Mental Health overview of PTSD research
- PubMed: Repeated Ketamine Infusions for Chronic PTSD — Feder et al. (2021) follow-up study on repeated infusions for PTSD
Share